Home Ideas & Research Indexes Hedge Funds Portfolios My tickerspy Newswire
Enter ticker(s) QQQ: 62.88 +0.67%   SPY: 135.45 +0.19%
Quote Spy FOLD NEW Message Board  
Click to close X

Visit a stock's Spy page to see who else is tracking it and who else is talking about it. Spy pages also list institutional holders.


Amicus Therapeutics (FOLD)

@ 1:43 PM
Click the portfolio to add FOLD:
Close [X]
+ Add FOLD to Portfolio
  
  Last Trade: $6.78 -0.01 (-0.15%)
  Volume: 210,804 165% of avg daily volume
       
  Avg Volume: 163,727
3-Month Chart (Larger chart w/volume)
Close [X]
1m  3m  6m  1y  2y
  Day's Range: 6.70 - 6.94
  Open: 6.88
  Previous Close: 6.79
  52-wk Range: 2.10 - 8.12
  Market Cap: 236.3M
  P/E: -4.5
  Div Yield: $0.00 (0.00%)
Indexes
Biotechnology Stocks (-0.5%)
Spy FOLD

? Pro holders
? Member holders
? Items submitted
Additional FOLD resources



Customize Links
To see which Pros and tickerspy members own FOLD Sign up now
Latest FOLD Notes & Links
View: Headlines   |   Message Board   |   Portfolio Notes  

Amicus Therapeutics Presents Preclinical Studies of Chaperone AT3375 for Gaucher Disease
FOLD  
Linked by GlobeNewswire - February 09, 12:40PM from (www.globenewswire.com)
CRANBURY, N.J., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Amicus Therapeutics to Announce Fourth Quarter and Full-Year 2011 Financial Results on February 13, 2012
FOLD  
Linked by GlobeNewswire - February 08, 09:30AM from (www.globenewswire.com)
CRANBURY, N.J., Feb. 8, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Amicus Therapeutics Awarded Grant From Muscular Dystrophy Association for Pompe Disease Program
FOLD  
Linked by GlobeNewswire - February 07, 07:30AM from (www.globenewswire.com)
CRANBURY, N.J., Feb. 7, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Amicus Therapeutics Announces Posters and Presentations at Lysosomal Disease Network WORLD Symposium
FOLD  
Linked by GlobeNewswire - January 30, 07:30AM from (www.globenewswire.com)
CRANBURY, N.J., Jan. 30, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that four presentations  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Amicus Therapeutics Appoints Bradley L. Campbell as Chief Business Officer
FOLD  
Linked by GlobeNewswire - January 23, 07:30AM from (www.globenewswire.com)
CRANBURY, N.J., Jan. 23, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Amicus Therapeutics Provides Full-Year 2012 Strategic Outlook and Financial Guidance
FOLD  
Linked by GlobeNewswire - January 09, 07:30AM from (www.globenewswire.com)

CRANBURY, N.J., Jan. 9, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today provided its business outlook  more ...

Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Amicus Therapeutics Announces Positive Preliminary Results From Ongoing Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Study for Fabry Disease
FOLD  
Linked by GlobeNewswire - January 06, 07:30AM from (www.globenewswire.com)
CRANBURY, N.J., Jan. 6, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced preliminary results from  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Amicus Therapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
FOLD  
Linked by GlobeNewswire - December 22, 01:00PM from (www.globenewswire.com)
CRANBURY, N.J., Dec. 22, 2011 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley,  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Amicus Therapeutics Completes Enrollment of 67 Patients in Phase 3 Study of Migalastat HCl for Fabry Disease
FOLD  
Linked by GlobeNewswire - December 19, 07:30AM from (www.globenewswire.com)
CRANBURY, N.J., Dec. 19, 2011 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Amicus Therapeutics Announces First Patient in Phase 2 Study for Pompe Disease
FOLD  
Linked by GlobeNewswire - December 01, 07:30AM from (www.globenewswire.com)

CRANBURY, N.J., Dec. 1, 2011 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at  more ...

Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Page 1 2 3 4 5



Close [X]
Select the external links you'd like on the quote and portfolio pages. We recommend 5 to 6 links. Request a new resource.
Profile/Financials
Yahoo! Profile
Yahoo! Key Stats
MSN Financials

Analysts
Nasdaq Analysts
Yahoo! Estimates
Charts / TA
Clearstation
Google Charts
StockCharts

Subscription
Insiderscore
10k Wizard
CallStreet
Other
Short Interest
SEC Filings
Insiders
Fool CAPS


Request a new resource